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Perturbation of gut microbiota decreases
susceptibility but does not modulate
ongoing autoimmune neurological disease
Clemens Gödel1,2, Birgit Kunkel3, Alireza Kashani4, Hans Lassmann5, Manimozhiyan Arumugam3 and
Gurumoorthy Krishnamoorthy3*
Abstract
The gut microbiota regulates the host immune and nervous systems and plays an important role in the
pathogenesis of autoimmune neurological disease multiple sclerosis (MS). There are considerable efforts currently
being undertaken to develop therapies for MS based on the modulation of microbiota. Evidence from experimental
models suggests that the manipulation of microbiota through diet or antibiotics prior to the disease development
limits disease susceptibility. However, it is currently unclear if microbiota manipulation therapies would also have an
impact on ongoing neurological disease. Here, we examined the effect of antibiotic-based microbiota modulation
in spontaneous experimental autoimmune encephalomyelitis (EAE) mouse models of MS before and after the onset
of autoimmune disease. Prophylactic antibiotic treatment led to a significant reduction of susceptibility to
spontaneous EAE. In contrast, antibiotic treatment after the onset of spontaneous EAE did not show a significant
amelioration. These results reveal that the perturbation of gut bacteria alters disease susceptibility but has minimal
impact on the ongoing neurological disease.
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Introduction
Advances in DNA sequencing and bioinformatics tech-
nologies in the last two decades led to an exponential in-
crease of studies that investigated the role of the
microbiome, in particular, gut microbiome, in several
diseases. This surge in interest has specifically garnered
attention in clinical settings due to their potential appli-
cations in clinical practice [1, 2]. The importance of
microbiota in specific diseases has been shown predom-
inantly in animal models or by comparing the commu-
nity structure of the gut microbiota in patients
compared to controls. Most of the results that have
shown a causal relationship with the microbiota to the
disease pathogenic processes have used germ-free (GF)
mice or manipulation of microbiota prior to the disease
development. Based on this, it is assumed that gut
microbiota manipulation would have therapeutic bene-
fits. However, the relative importance of microbiota in
already ongoing diseases is unclear.
We and others have previously shown that gut micro-
biota is essential for the central nervous system (CNS)-
specific autoimmune disease, multiple sclerosis (MS) [3–
5]. In animal models of MS, manipulation of microbiota
prior to the development of the disease either by antibi-
otics [6–8] or diet [9–11] modulated disease severity and
incidence. However, it is unclear if the modulation of
microbiota in ongoing disease would also have an impact
on the disease progression. Here, using spontaneous
EAE mouse models of MS, we studied the relative
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importance of the microbiota before and after the devel-
opment of the neurological disease.
Methods
Mice, antibiotic treatment, and scoring
OSE (2D2 × IgHMOG) C57BL/6 [12] and RR SJL/J [13]
mice were bred and housed at the animal facility of the
Max Planck Institute of Biochemistry, Martinsried. Mice
were treated with ampicillin (1 g/L), neomycin (1 g/L),
and vancomycin (1 g/L) dissolved in autoclaved drinking
water. To increase the liquid intake, sweetener was
added and the control mice also received the same
sweetener in their drinking water. Since the disease de-
velopment in the OSE model starts as early as 5 weeks
after birth [12], OSE mice were given antibiotics either
at 2 or 4 weeks of age in prophylactic treatment experi-
ments. For therapeutic treatment experiments, mice that
developed spontaneous EAE symptoms (after first signs
of EAE) were randomly assigned to either control or
antibiotic group and treated for 2 weeks as above. Clin-
ical disease was assessed according to the standard 5-
point scale [12, 13]. All animal procedures were ap-
proved by Regierung von Oberbayern (Munich,
Germany).
Histology
Animals were sacrificed 2 weeks after treatment. The
brain and spinal cords were fixed in formaldehyde and
embedded in paraffin. The neuropathological analysis
was done on paraffin sections of the brain (including
optic nerve and chiasm) and the spinal cord stained with
hematoxylin/eosin for inflammation and Luxol fast blue
myelin stain for demyelination. Semiquantitative assess-
ment of the degree of inflammation and demyelination
was performed in the spinal cord and the optic nerves.
The entire spinal cord was embedded in 10 standardized
tissue blocks. Inflammation was quantified by counting
the number of perivenous inflammatory infiltrates and
providing their average number per spinal cord cross
section per animal. The extent of demyelination in the
spinal cord was evaluated according to the following
scoring: 0, no demyelination; 1, perivenous and subpial
demyelination; 2, confluent demyelinated plaques; and 3,
extensive demyelination affecting more than half of the
spinal cord cross section. The extent of demyelination in
the optic nerve was evaluated according to the following
scoring: 0, no demyelination; 1, perivenous demyelin-
ation; 2, perivenous and subpial demyelination; 3, con-
fluent demyelinated plaques; and 4, complete focal
demyelination in the optic nerve. Representative pictures
for the demyelination scores are given in Supplementary
Figure 2.
Cell isolation and flow cytometry
Isolation and phenotyping of immune cells by flow
cytometry were done as previously described [4]. For
the isolation of lymphocytes from the small intestine,
the intestine was collected in ice-cold Hank’s Bal-
anced Salt Solution (HBSS) buffered with 15 mM
Hepes. After careful removal of Peyer’s patches, fatty
tissue, and fecal contents, the intestine was opened
longitudinally and cut into small pieces. The intestinal
fragments were washed three times for 15 min in
HBSS containing 5 mM EDTA, 15 mM Hepes, and
10% fetal bovine serum (FBS). Next, intestinal pieces
were washed once for 5 min with stirring in Roswell
Park Memorial Institute medium (RPMI) containing
15 mM HEPES and 10% FBS, followed by an incuba-
tion step at 37 °C with stirring (550 rpm) in RPMI
with 15 mM HEPES, 10% FBS, and 100 U/ml collage-
nase D (Roche Diagnostics). The digested tissue was
washed twice in HBSS containing 5 mM EDTA, be-
fore the lymphocytes of the small intestine were re-
suspended in 5 ml of 40% Percoll (Sigma-Aldrich) and
overlaid on 2.5 ml of 80% Percoll. Percoll gradient
separation was performed by centrifugation at 780g
for 20 min at room temperature. Small intestinal lam-
ina propria lymphocytes were harvested from the
interphase of the Percoll gradient and washed once in
RPMI containing 15 mM Hepes and 10% FBS. After
isolation, cells were stained in FACS buffer (PBS con-
taining 1% BSA and 0.1% NaN3) with fluorochrome-
labeled Abs against CD45 (30-F11), CD4 (RM4-5),
B220 (RA3-6B2), CD11b (M1/70), and CD11c (N418).
For intracellular cytokine staining, cells were activated
with 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml
ionomycin (Sigma-Aldrich) in the presence of 5 μg/ml
brefeldin A (Sigma-Aldrich) for 4 h at 37 °C. After
surface staining, cells were fixed and permeabilized
using the Transcription Factor Staining Buffer Set
(eBioscience) and stained intracellularly using the fol-
lowing antibodies against IFN-γ (XMG1.2), IL17
(TC11-18H10), IL-22 (1H8PWSR), and TNFα (MP6-
XT22). All antibodies were purchased from BD Phar-
mingen, eBioscience, or BioLegend. Cells were ac-
quired on FACSVerse, and analysis was performed
using FlowJo (TreeStar) software.
Culture of bacteria
Fecal pellets were collected from the mice and frozen at
− 80 °C until analysis. Fecal pellets of mice were weighed,
suspended, and serially diluted in sterile PBS. One hun-
dred microliters of the diluted fecal homogenates were
plated on Bile Esculin (BE) agar plates. After overnight
incubation at 37 °C, the colony-forming units (c.f.u.)
were determined and expressed as c.f.u./g of feces.
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Bacterial DNA extraction from mouse feces and 16S RNA
sequencing
Fecal pellets were collected from the mice and frozen at
− 80 °C until analysis. Bacterial genomic DNA was ex-
tracted from fecal pellets using QIAamp DNA Stool
mini kit with bead beating (Qiagen). An amplicon library
targeting V3 and V4 regions of the 16S ribosomal RNA
gene was amplified by PCR with specific primers and se-
quenced on an Illumina MiSeq instrument (2 × 300-bp
paired-end reads). Paired reads were merged to assemble
a contig within a length of 456 ± 11 base pairs. Contigs
with low base pair quality scores as well as those with
misprimes were removed. Sequences were assigned to
the same species-level OTU if they had a 97% sequence
identity. To identify differentially abundant members of
the gut microbiome between the groups, we performed
a Wilcoxon rank-sum test on OTU relative abundances
and adjusted the P values for multiple testing using the
false discovery rate (FDR). OTUs with an adjusted P
value less than 0.05 were considered as differentially
abundant.
Quantitative PCR for bacteria
Bacterial genomic DNA was extracted from fecal pellets
using the QIAamp DNA Stool mini kit (Qiagen). Total or
enterococci 16S rRNA gene-specific PCR was performed.
Primers for enterococci 16S rRNA gene were as follows:
GTGCCAGCMGCCGCGGTAA and GCCTCAAGGG
CACAACCTCCAAG. Primers for total 16S rRNA gene
were as follows: ACTCCTACGGGAGGCAGCAGT and
ATTACCGCGGCTGCTGGC. All reactions were per-
formed using the SYBR Green qPCR master Mix (Thermo
Fisher Scientific) following the manufacturer’s instructions
and measured using a 7900HT real-time PCR System or
Quantstudio 3 (Applied Biosystems). The absolute quan-
tity of 16S rRNA gene copies was calculated using a stand-
ard curve generated with a plasmid encoding enterococci
or lactobacilli (for total 16S rRNA) 16S rRNA gene and
expressed as gene copies per nanogram of DNA.
Statistics
GraphPad Prism 6 (GraphPad Software, Inc.) was used
for the statistical analysis. P values < 0.05 were consid-
ered to be significant.
Results and discussion
Previous studies have shown that manipulation of micro-
biota with prophylactic antibiotic treatment suppressed
the severity of autoimmune encephalomyelitis in actively
induced EAE models [6–8]. To avoid potential influence
of the adjuvant CFA (commonly used in active EAE
models) in treatment-related immune responses, we
treated a spontaneous experimental autoimmune enceph-
alomyelitis mouse model (OSE (opticospinal
encephalomyelitis)) [12] with a mixture of antibiotics be-
fore the development of the disease. OSE mice were given
an antibiotic mixture for 2 weeks starting from either 2 or
4 weeks after birth (Fig. 1 a). After 2 weeks of antibiotic
treatment, mice were given access to normal tap water.
The effect of antibiotic treatment was clearly visible in the
cecum size. The antibiotic-treated mice had significantly
larger cecum than control mice (Fig. 1c). Also, antibiotic-
treated mice had a slight increase in body weight when
compared to control mice (Fig. 1b). Similar to previous re-
ports in actively induced EAE models [6–8], prophylactic
antibiotic treatment either at 2 or 4 weeks after birth sup-
pressed the development of spontaneous EAE to a greater
extent (Fig. 1c and data not shown). Apart from antibi-
otics, we have previously shown that prophylactic dietary
fiber supplementation which alters gut microbiota also
prevented the development of spontaneous EAE by modu-
lating microbiota [9]. Analysis of intestinal immune cells
populations showed no changes in the frequencies of
CD4+ T cells, B220+ B cells, CD11b+ macrophages, and
CD11c+ dendritic cells. However, there was a decrease in
the frequencies of proinflammatory IL-17- and TNFα-
producing T cells while IFNγ- and IL-22-producing T
cells were unaltered (Fig. 1d).
Since antibiotics can alter the composition of the
microbiota, we analyzed the fecal microbiota by 16S
ribosomal RNA (16S rRNA) gene amplicon sequen-
cing. Gut bacterial communities between control and
antibiotic-treated mice were compared in terms of di-
versity (alpha and beta) and composition. The beta
diversity analysis revealed distinct clustering of con-
trol and antibiotic-treated mice, suggesting that anti-
biotics significantly altered the overall bacterial
community composition. The alpha diversity analysis
revealed that species diversity (Shannon index) is sig-
nificantly reduced in the antibiotic-treated mice
(Fig. 1e). The analysis of the abundance profiles of
bacterial populations showed various alterations in
the microbiota of antibiotic-treated mice (Fig. 1f).
While many of the significantly altered microbial or-
ganisms were depleted in antibiotic-treated mice, we
found an increased representation of Enterococcus
durans species together with E. coli and other species
within the genera Akkermansia, Bacteroides, and
Blautia in antibiotic-treated mice (Fig. 1g). We con-
firmed the increased abundance of the enterococci by
quantitative PCR using bacterial DNA isolated from
fecal pellets and by culture on the Bile Esculin agar
plate, which allows the selective growth of Entero-
coccus species (Supplementary Fig. 1). Enterococcus
durans has been shown to have anti-inflammatory
properties. It reduced the expression of proinflamma-
tory cytokines IL-1β and IL-17A and increased the
proportion of regulatory T cells in a DSS colitis
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model, which resulted in the improvement of clinical
scores and pathology [14]. However, our attempts to
stably colonize enterococci in our OSE mice were not
successful likely due to the colonization resistance by
the indigenous bacteria. It is plausible that E. durans
along with other bacterial strains that are enriched
after antibiotic treatment induces anti-inflammatory
responses in our model.
Fig. 1 Antibiotic treatment prevents spontaneous CNS autoimmune disease. a Schematic view of the treatment protocol. Significant increase in
the cecum size following antibiotic treatment. Exemplary pictures are shown. b Bodyweight change in percent compared to the initial weight.
n = 10 per group. c Incidence of spontaneous EAE in a cohort of antibiotic-treated OSE mice. n = 15 per group. *P < 0.05 (Gehan-Breslow-
Wilcoxon test). d Frequencies of IL-17, IFNγ, IL-22, and TNF-α-producing CD4+CD45+cells in the small intestine from control and antibiotic-treated
mice. n = 6–8 mice per group. *P < 0.05 (Mann-Whitney test). e Comparison of fecal microbiome alpha-diversities (Shannon index) of control and
antibiotic-treated mice. f Comparison of fecal microbiome phylum compositions in control and antibiotic-treated mice. g Fold changes of
significant OTUs identified by the Wilcoxon rank-sum test as differentially abundant in fecal microbiomes. OTUs are colored by phylum affiliation
and grouped by the highest taxonomic resolution
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Having established that antibiotic treatment alters
microbiota composition and protects OSE mice from
spontaneous EAE development when applied prophy-
lactically, we set out to investigate the impact of anti-
biotic treatment in clinically established neurological
disease. We randomly assigned mice that have devel-
oped EAE and gave antibiotics for 2 weeks. Over the
course of 2 weeks, we monitored the body weight and
their clinical symptoms. The mice that were treated
with antibiotics continued to show increased body
weight similar to prophylactic antibiotic-treated mice
(Fig. 2a). The bacterial load as measured by 16S
rRNA gene PCR was also significantly reduced after
antibiotic treatment (Supplementary Fig. 3a). How-
ever, we did not find significant changes in the dis-
ease course during our observation period (Fig. 2b, c).
Histological analysis also showed no differences in the
inflammatory infiltrates as well as demyelination in
the spinal cord and optic nerve (Fig. 2d–f). To rule
out model-specific effects, we applied a similar treat-
ment to another spontaneous relapsing-remitting (RR)
EAE model on a different genetic background (SJL/J)
[13]. Again, antibiotic treatment reduced the bacterial
load but had no effect on the disease course (Fig. 2g
and Supplementary Fig. 3b). In summary, these data
suggest that the microbiota manipulations by anti-
biotic treatment are not beneficial in a therapeutic
regimen.
Conclusions
The data presented here show that, in the context of
CNS autoimmunity, microbiota manipulation is benefi-
cial prior to the disease development but not after estab-
lished disease. Our data reinforce observations that
microbiota manipulations through antibiotics and diet
have an impact on inflammatory immune responses that
are necessary for the induction of the disease [6, 8–10]
while having minimal impact on remyelination processes
that are important for the resolution of the disease [15].
Our report provides an important cautionary note that
more studies are needed to understand whether micro-
biota manipulation therapies in clinically established dis-
eases would be beneficial. This is especially important
for extra-intestinal organ-specific autoimmune diseases
such as MS, where the disease-promoting events may
occur elsewhere than the intestine. However, it is pos-
sible that the microbiota manipulation in combination
with other immunomodulatory drugs will still be useful
to mitigate disease symptoms.
Fig. 2 Antibiotic treatment does not affect ongoing CNS autoimmune disease. a Bodyweight change in percent compared to the initial weight
of EAE-affected OSE mice treated with antibiotics. n = 10 per group. b Mean cumulative score of EAE-affected OSE mice treated with antibiotics.
n = 10 per group. c Mean clinical score of sick OSE mice treated with antibiotics. n = 10 per group. Quantification of the inflammatory score (d),
demyelination score (e) of spinal cord, and demyelination score (f) of the optic nerve after 2 weeks of antibiotic treatment. n = 10 per group. g
Mean clinical score of EAE-affected RR SJL/J mice treated with antibiotics. n = 6 per group
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Additional file 1 Supplementary Figure 1. Antibiotics treatment
alters microbiota. (a) 16 s rRNA gene copies of Enterococci in fecal pellets
of antibiotics treated OSE mice measured by quantitative real-time PCR.
n = 5 per group. (b - c) Quantification of Enterococci in fecal pellets by
culture on Bile Esculin agar in antibiotics treated OSE mice. Serial dilu-
tions of fecal samples collected 6 weeks after the antibiotics treatment
were plated on Bile Esculin agar plates. n = 4 per group.
Additional file 2 Supplementary Figure 2. Representative images of
semi-quantitative demyelination scores on cross-sections of the spinal
cord and optic nerve stained with Luxol fast blue myelin stain. Spinal
cord: SC1: Perivenous and subpial demyelination; SC2: large confluent
demyelinated plaques; SC3: extensive demyelination affecting more than
half id the spinal cord cross-section. Optic nerve: ON0: no demyelination;
ON1: perivenous demyelination; ON2: perivenous and subpial demyelin-
ation; ON3: confluent demyelinated plaques; ON4: complete focal demye-
lination in the optic nerve.
Additional file 3 Supplementary Figure 3. Antibiotics treatment in
EAE affected mice reduces microbial load. Total 16 s rRNA gene copies in
fecal pellets of antibiotics treated OSE mice (a) and RR mice (b)
measured by quantitative real-time PCR. n = 4–7 per group. *p < 0.05
(Mann-Whitney test).
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